- Home >
- Life Sciences >
- Pharmaceutical >
Monoclonal Antibodies: Pipeline Analysis and Competitive Assessment
Monoclonal Antibodies: Pipeline Analysis and Competitive Assessment
- Report price : $ 3 750
- Publication date : August 2009
Monoclonal Antibodies: Pipeline Analysis and Competitive Assessment
In the nearly 35 years since the first process for creating mAbs was introduced, they have remained a centerpiece of the growing biotechnology industry. Thirty therapeutic mAbs have been approved around the world, including 23 in the United States. A number of these drugs have attained blockbuster status, with sales reaching the coveted billion-dollar mark and well beyond. Rituxan, Remicade, Avastin, Herceptin, and Humira alone generated sales of over $4 billion each in 2008, and global sales for this entire sector surpassed $30 billion last year.
Key challenges and implications presented in this new report include:
- Future products and their indications
- Merits of human versus chimeric structures
- Costs of mAb therapy and the US healthcare debate
- Clinical pipeline with over 250 candidates
- A focus on "engineered" antibodies
Monoclonal Antibodies: Pipeline Analysis and Competitive Assessment reviews the broad drug development effort that is focused on bringing improved mAb-based products to the market, concentrating on those used for therapeutic applications. It surveys the latest technologies being applied to the development of these compounds and profiles the major companies, drugs, and projects. It then draws conclusions about the future market potential for mAbs and discusses the major challenges faced by the industry.
The biotech industry devoted years to reducing the immunogenicity of mAbs, developing the technologies—detailed in this report—to progress from chimeric, to humanized, to fully human antibodies. These succeeding generations of mAbs have demonstrated incremental improvements in safety and activity, and the industry is currently in the middle of a major shift toward humanized and human products.
Much work has also been done on altering antibodies’ outward form to boost their efficacy, enabling them to more readily penetrate tumors, enhancing their ability to stimulate beneficial immune responses, or otherwise improving their characteristics. Into this realm fall such constructions as antibody fragments, diabodies, synthetic antibodies, bispecific antibodies, and antibody conjugates. This report looks at some of the engineered forms of antibodies and the companies that are leading the way in this research. Other complementary technologies, such as PEGylation and glycosylation, are also presented.
Monoclonal Antibodies: Pipeline Analysis and Competitive Assessment presents an analysis for the current state of mAb drug development. It identifies more than 250 therapeutic products now in clinical trials, which are largely concentrated in the areas of cancer, immunological and inflammatory diseases, as well as infectious diseases. Beyond these, hundreds more candidates are at the preclinical stage of development. Reviewed here are the products that are already available, those in clinical development, and those still at the preclinical stage that are likely to play an important role in the advancement of the field.
Please note, this report is delivered as a zip file.
RELATED REPORTS
Ion Channel Modulator Pipelines: Targets and Agents in Development
- $ 2 995
- September 2009
Ion channels represent a significant opportunity to address an underexploited class of therapeutic targets. Nearly 150 novel ion channel modulators are reported to be in clinical development. This report examines:Ion channel modulators in clinical development and their potential Improved molecular u ...
Industries : Pharmaceutical
Pharmaceutical & Medicine Manufacturing in the US - Industry Risk Rating Report
- $ 803
- October 2009
INDUSTRY RISK RATINGS REPORTThis is the replacement for May 2009 edition of Pharmaceutical & Medicine Manufacturing in the US Industry Risk Ratings Report.Industry Risk Ratings SynopsisThis Industry Risk Ratings report evaluates the inherent risks associated with the Pharmaceutical & Medicine Manu ...
Industries : Pharmaceutical
Immunotherapies and Vaccines for Nontraditional Indications
- $ 2 995
- October 2009
Novel applications of immunotherapies and vaccines beyond prevention and treatment of infectious diseases and cancer are reviewed. Those discussed typically target molecules not normally targeted by the immune system. This report:Covers a wide range of conditions for which immunotherapies may be eff ...
Industries : Pharmaceutical
Pharmaceutical Speaker Programs: Measuring ROI and Communicating Value
- $ 7 695
- September 2009
Adapt to a New Environment and Prove Speaker Programs' ValuePharmaceutical Speaker Programs provides innovative, actionable strategies and best practices that will make your speaker events more effective and generate better ROI. Our data benchmarks - developed from input from marketing executives, ...
Industries : Pharmaceutical
China Pharmaceutical Chain Industry Report, 2009
- $ 1 600
- October 2009
According to the chain drug stores ranking in China in 2009, top 100 enterprises in China pharmaceutical chain industry achieved the sales revenue of RMB57.24 billion in 2008, increasing by RMB13.33 billion (30.35%) than RMB43.91 billion in 2007. In 2008, the average profit margin of top 100 enterp ...
Industries : Pharmaceutical
Outsourcing Preclinical Studies to China
- $ 2 995
- July 2009
Within the past several years, a number of government labs as well as private and joint venture CRO’s have or will soon offer preclinical GLP study services to Western clients. This report, built on discussions and facility visits to the most advanced labs, provides a detailed view of the cu ...
Industries : Pharmaceutical
Data Mining in Drug Development and Translational Medicine
- $ 2 995
- July 2009
The biopharmaceutical industry is grappling not only with sheer data volume but with the ability of researchers to extract information through identification and contextual analysis of those data that are relevant to a particular set of investigations. This report examines:Techniques, technology, an ...
Industries : Pharmaceutical
Pharmacogenomics: Delivering on the Promise
- $ 2 995
- June 2009
Pharmacogenomics (PGx) is often considered “the great new wave” in medicine, promising better, safer, and more affordable healthcare. Yet its adoption and widespread use in the clinic is up against some tremendous challenges. This report considers:Drivers of PGx Applications of PGx in d ...
Industries : Pharmaceutical
Bioinformatics and Computational Biology: Bottlenecks and Options
- $ 2 995
- June 2009
The interdisciplinary fields of Bioinformatics and Computational Biology are locked in a high stakes race with analytical instrument developers and innovators. The pace and scope of change in many fields of biomedical research rivals what we once associated only with semiconductor devices. This repo ...
Industries : Pharmaceutical
Approaches to Reducing Phase II Attrition
- $ 2 995
- May 2009
Phase II is the critical development stage in which most clinical attrition occurs. This report focuses on approaches to improving R&D productivity in the pharmaceutical and biotechnology industries and considers:Leading-edge strategies being pursued to improve success rates of therapeutic candidate ...
Industries : Pharmaceutical
Related industries
Related companies
reportlinker.com © Copyright 2009. All rights reserved